Skip to content
TrialScanner

NCT05226507

A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian Cancer

Phase 1TerminatedNVCTLead

Registry record

Lead sponsor
Nuvectis Pharma, Inc.
Conditions
Advanced Solid Tumor; Ovarian Cancer; Ovarian Clear Cell Carcinoma; Ovarian Clear Cell Tumor; Ovarian Clear Cell Adenocarcinoma
Primary completion
Jan 1, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05226507 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.